166 related articles for article (PubMed ID: 37779754)
21. Progressive, refractory macrophage activation syndrome as the initial presentation of anti-MDA5 antibody positive juvenile dermatomyositis: a case report and literature review.
Stewart JA; Price T; Moser S; Mullikin D; Bryan A
Pediatr Rheumatol Online J; 2022 Feb; 20(1):16. PubMed ID: 35193600
[TBL] [Abstract][Full Text] [Related]
22. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
23. Graves' disease after exposure to the SARS-CoV-2 vaccine: a case report and review of the literature.
Takedani K; Notsu M; Ishiai N; Asami Y; Uchida K; Kanasaki K
BMC Endocr Disord; 2023 Jun; 23(1):132. PubMed ID: 37316819
[TBL] [Abstract][Full Text] [Related]
24. A case of Wong-type dermatomyositis treated with rituximab and IVIG.
Argobi Y; Fedeles F; Schoenfeld SR
Australas J Dermatol; 2021 Feb; 62(1):e86-e87. PubMed ID: 32671816
[TBL] [Abstract][Full Text] [Related]
25. MDA-5 associated rapidly progressive interstitial lung disease with recurrent Pneumothoraces: a case report.
Alqatari S; Riddell P; Harney S; Henry M; Murphy G
BMC Pulm Med; 2018 Apr; 18(1):59. PubMed ID: 29665800
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic Delays for Non-melanoma Skin Cancers in Renal Transplant Recipients during the COVID-19 Pandemic: What is Hiding Behind the Mask?
Mokos M; Bašić-Jukić N
Acta Dermatovenerol Croat; 2021 Jul; 29(2):111-113. PubMed ID: 34477079
[TBL] [Abstract][Full Text] [Related]
27. Dermatomyositis Flare After a COVID-19 Infection Successfully Treated with Rituximab: A Case Report and Literature Review.
Albakri AM; Subki AH; Albeity A; Halabi H
J Inflamm Res; 2022; 15():6047-6053. PubMed ID: 36348728
[TBL] [Abstract][Full Text] [Related]
28. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
29. Progressive interstitial lung disease in hypomyopathic dermatomyositis in the COVID-19 pandemic: A case report.
Wang S; Lyu Y; Xu L; Zhang W
Int J Rheum Dis; 2023 Apr; 26(4):759-763. PubMed ID: 36502514
[TBL] [Abstract][Full Text] [Related]
30. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
Stowe J; Miller E; Andrews N; Whitaker HJ
PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378
[TBL] [Abstract][Full Text] [Related]
31. A case of myopericarditis recurrence after third dose of BNT162b2 vaccine against SARS-CoV-2 in a young subject: link or causality?
Mapelli M; Amelotti N; Andreini D; Baggiano A; Campodonico J; Moltrasio M; Majocchi B; Mantegazza V; Vignati C; Ribatti V; Catto V; Sicuso R; Moltrasio M; Pontone G; Agostoni P
Eur Heart J Suppl; 2022 May; 24(Suppl C):C243-C247. PubMed ID: 35602257
[TBL] [Abstract][Full Text] [Related]
32. Rare Cases of Polymyalgia Rheumatica After Receiving COVID-19 Vaccinations.
Furr T; Garg M
Cureus; 2023 Apr; 15(4):e37782. PubMed ID: 37091488
[TBL] [Abstract][Full Text] [Related]
33. A mild form of dermatomyositis as a prodromal sign of lung adenocarcinoma: a case report.
Papakonstantinou E; Kapp A; Raap U
J Med Case Rep; 2016 Feb; 10():34. PubMed ID: 26851947
[TBL] [Abstract][Full Text] [Related]
34. Myoclonus status revealing COVID 19 infection.
Ben Mohamed D; Zouari R; Ketata J; Nabli F; Blel S; Ben Sassi S
Seizure; 2023 Jan; 104():12-14. PubMed ID: 36446232
[TBL] [Abstract][Full Text] [Related]
35. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
36. Gross hematuria can be an impact of severe acute respiratory syndrome coronavirus 2 vaccination on immunoglobulin A nephropathy: a case report.
Kanamori H
J Med Case Rep; 2022 Jul; 16(1):273. PubMed ID: 35818083
[TBL] [Abstract][Full Text] [Related]
37. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
38. Inflammatory myopathy following coronavirus disease 2019 vaccination: A systematic review.
Ding Y; Ge Y
Front Public Health; 2022; 10():1007637. PubMed ID: 36339243
[TBL] [Abstract][Full Text] [Related]
39. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
40. Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks.
Esmaeilzadeh A; Maleki AJ; Moradi A; Siahmansouri A; Yavari MJ; Karami P; Elahi R
Expert Rev Vaccines; 2022 Oct; 21(10):1377-1394. PubMed ID: 35986451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
